Recombinant Human VEGF-C Protein, Two N- s, His- & SUMO-

Vascular Endothelial Growth Factor C (VEGF-C) is a pivotal protein involved in lymphangiogenesis, the process of forming new lymphatic vessels, and is a key regulator of endothelial cell function. Its role in promoting lymphatic endothelial cell proliferation and migration has made it a significant focus of research in both normal physiology and pathological conditions, such as cancer, inflammation, and lymphedema. In the context of tumor biology, VEGF-C is particularly notable for its capacity to facilitate metastasis by enhancing lymphatic spread of cancer cells, which underscores its potential as a therapeutic target. Recombinant VEGF-C protein studies have been instrumental in elucidating the molecular mechanisms underlying lymphangiogenesis and have paved the way for the development of novel therapeutic strategies aimed at modulating this process. Additionally, the exploration of VEGF-C’s interaction with its receptors, VEGFR-2 and VEGFR-3, and subsequent signaling pathways has highlighted its importance in vascular biology. Understanding the functional aspects of VEGF-C through recombinant protein studies not only contributes to a deeper comprehension of vascular development but also offers insights into innovative interventions for diseases characterized by aberrant lymphatic function. This has spurred interest in creating VEGF-C-based biomolecules or inhibitors that can regulate its activity, fostering a burgeoning field of research dedicated to targeting lymphangiogenesis therapeutically. As such, the study of recombinant VEGF-C continues to be a critical area of inquiry with wide-ranging implications in oncology, regenerative medicine, and beyond.